Company: Regeneron Pharmaceuticals
Job title: Senior Director of Oncology
Jessica Kirshner, Senior Director of Oncology at Regeneron Pharmaceuticals, leads a team of scientists responsible for discovering and developing immunoncology therapeutics. Her team focuses on developing CD3-bispecific antibodies and antibody-drug conjugates for various tumor indications, and is active in Regeneron’s CAR T cell collaborations. She has led three programs from discovery to first in human studies: REGN1979, targeting CD20 on lymphoid malignancies; REGN4018, targeting MUC16 in ovarian cancer; and REGN5458, targeting BCMA in multiple myeloma. During her career she has focused on target validation, drug discovery and drug development. Dr. Kirshner earned her Ph.D. in Biomedical Sciences at UCSF, and subsequently performed post-doctoral work on tumor virology at Harvard Medical School. She has authored numerous publications and is an inventor on multiple filed and issued US and international patents.
A Novel Class of Antibodies to Enhance CD3 Bispecific Activity in Solid Tumors 10:30 am
day: Day Two